Follicular fluid and serum vascular endothelial growth factor, interleukin (IL)-1β and glycodelin concentrations: comparison between long-gonadotropin-releasing hormone (GnRH)-agonist and GnRH-antagonist cycles: a randomized controlled trial. (13th June 2014)

• Record Type: Journal Article
• Authors: Aydin, Yunus; Hassa, Hikmet; Isikci, Tugba; Colak, Omer
• Is Part Of: Gynecological endocrinology. Volume 30:Number 10(2014:Oct.)
• Page Start: 734
• Page End: 738
• Publication Date: 2014-06-13
• Subjects: Glycodelin -- gonadotropin-releasing hormone agonist -- gonadotropin-releasing hormone antagonist -- interleukin (IL)-1β -- vascular endothelial growth factor; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.3109/09513590.2014.929655
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: In this randomized controlled trial, we aimed to examine whether differences exist among patients who underwent assisted reproductive technology treatment with a long-GnRH-agonist compared to a GnRH-antagonist protocol in terms of levels of follicular fluid (FF) and serum concentrations of vascular endothelial growth factor (VEGF), glycodelin and interleukin (IL)-1β on the day of oocyte pick-up (OPU). In 80 infertile couple with male factor or unexplained infertility, 40 women stimulated with GnRH-antagonist protocol and 40 women with the long-GnRH-agonist protocol. FF and blood serum samples were obtained simultaneously from 80 women during the OPU procedure and the concentrations of VEGF, IL-1β and glycodelin were measured with commercially available kits. Concentrations of FF VEGF, IL-1β and glycodelin were not significantly different in the long-GnRH-agonist and GnRH-antagonist groups, and neither were serum concentrations of VEGF, IL-1β and glycodelin. According to our results in at least, we can say that minor differences between these protocols in terms of clinical pregnancy do not depend on VEGF, glycodelin or IL-1β. Chinese abstract: 该随机对照试验目的是探讨接受GnRH-a长方案与GnRH拮抗方案患者取卵日（OPU）卵泡液（FF）、血管内皮生长因子（VEGF）的血浆浓度、白介素（IL）1-b水平及妊娠相关蛋白浓度是否存在差别。80个因男性不孕或不明原因不孕妇女中40名采用GnRH-a长方案，40名采用GnRH拮抗方案。其中FF和血清样本通过取卵日取卵过程获得，VEGF、IL -1b及妊娠相关蛋白浓度通过已经商业化的试剂盒测量。两种方案中FF、VEGF、IL -1b及妊娠相关蛋白浓度无明显区别，VEGF、IL -1b及妊娠相关蛋白的血清浓度也无明显区别。根据结果，我们至少可以说明就临床妊娠方面而言，这两种方案的微小差别并不依赖VEGF、IL -1b及妊娠相关蛋白的变化。